CytoGenix Inc. to Receive a Research Grant From National Health Institute/NIH.Business Editors & Health/Medical Writers
HOUSTON--(BUSINESS WIRE)--March 26, 2002
CytoGenix Inc. (OTCBB OTCBB
See OTC Bulletin Board (OTCBB). :CYGX) announced today that it has received a Small Business Technology Transfer Research (STTR STTR Small Business Technology Transfer Program
STTR Small Technology Transfer Innovation Research ) Phase I grant from NIH "Not invented here." See digispeak.
NIH - The United States National Institutes of Health. to test the company's proprietary single-stranded DNA DNA: see nucleic acid.
or deoxyribonucleic acid
One of two types of nucleic acid (the other is RNA); a complex organic compound found in all living cells and many viruses. It is the chemical substance of genes. (ssDNA) expression systems in a transgenic trans·ge·nic
1. Of, relating to, or being an organism whose genome has been altered by the transfer of a gene or genes from another species or breed: transgenic mice.
2. mouse model. This grant will support research both at CytoGenix and in the laboratory of our collaborator, Dr. Peter Glazer at Yale University Yale University, at New Haven, Conn.; coeducational. Chartered as a collegiate school for men in 1701 largely as a result of the efforts of James Pierpont, it opened at Killingworth (now Clinton) in 1702, moved (1707) to Saybrook (now Old Saybrook), and in 1716 was , to develop a mouse model producing triplex-forming oligonucleotides (TFOs) using ssDNA expression systems.
Dr. Glazer, professor at the Department of Therapeutic Radiology and Genetics at Yale University, is a world renowned expert in the field of molecular therapy using triplex-forming oligonucleotides. He is also one of the earliest members of CytoGenix's scientific advisory board (SAB). Dr. Glazer's laboratory has recently reported results published in the Nucleic Acid nucleic acid, any of a group of organic substances found in the chromosomes of living cells and viruses that play a central role in the storage and replication of hereditary information and in the expression of this information through protein synthesis. Research Journal using CytoGenix's ssDNA expression systems to generate triplex-forming oligonucleotides that mediate target specific gene knockouts or genome modification.
Dr.Yin Chen, vice president of research and development at CytoGenix Inc., who is also the principal investigator Noun 1. principal investigator - the scientist in charge of an experiment or research project
scientist - a person with advanced knowledge of one or more sciences of the STTR grant, notes, "Our ssDNA expression technology is receiving growing recognition by the scientific community as well as biotech and pharmaceutical companies. This recognition was augmented by NIH's peer review of our STTR grant. The reviewers chosen by NIH are acknowledged experts in their fields. Winning such a grant is a significant milestone in the development of CytoGenix's technology."
Dr. Malcolm Skolnick, chairman/CEO at CytoGenix Inc. notes, "One of the NIH reviewers commented that our...proposal is highly innovative and represents a potentially superior approach for delivering single-chain oligonucleotides for targeted gene manipulation. We expect that completing the grant-supported activities will add to the strength of our technology and bring us closer to the goals of its commercialization."
CytoGenix Inc. is a Houston-based biopharmaceutical company pioneering research and development of its proprietary ssDNA expression technology. CytoGenix's ssDNA expression system has been shown to be useful in reducing or eliminating the harmful proteins involved in a broad range of diseases and conditions such as cancer. This technology also has potential applications in the target validation and development of next-generation genomic drugs.
SAFE HARBOR Safe Harbor
1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated.
2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. : Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the Web site at www.cytogenix.com.